TECHNOLOGY FOCUS - ORGANIC CHEMISTRY - Preparation (Claimed): Preparation of (I) comprises: either (a) forming a suspension of amorphous 1-( beta -D-glucopyranosyl)-4-methyl-3-(5-(4-fluorophenyl)-2-thienylmethyl)benzene in water, (b) subjecting the suspension to a mechanical particle size reduction process, (c) isolating the obtained crystals, and (d) subjecting the crystals to an atmosphere having a relative humidity of greater than 30% at 20 plus minus 5 degrees C; or (i) forming a suspension (U) comprising water and seed crystals of (I), (ii) forming a solution (O) comprising a water-miscible organic solvent and (I), (iii) forming a mixture (M) comprising not more than 13 vol.% of a water miscible organic solvent by combining solution (O) and suspension (U), and (iv) crystallizing (I), where the seed crystals are characterized by a X-ray powder diffractogram comprising characteristic peaks at 2-theta angles as given in the specification when measured at a temperature of 15-25 degrees C using copper-Kappa radiation having a wavelength of 0.15419 nm. Preferred Process: The crystals of (I) obtained in the step (iv) are isolated and subjected to an atmosphere having a relative humidity of greater than 30% or less than 45% at 20 plus minus 5 degrees C. Preferred Components: (I) has a water content of 0.1-8%, and an X-ray powder diffraction pattern comprising peaks at 2-theta angles as given in the specification, and is present in lath-shaped. The X-ray powder diffraction pattern of (I) is substantially the same as the X-ray powder diffraction pattern shown in figure 1 and 3 of the specification when measured using copper-potassium- alpha radiation. ACTIVITY - Antidiabetic; Ophthalmological; Nephrotropic; Neuroprotective; Vulnerary; Antilipemic; Anorectic; Hemostatic; Metabolic; Cardiovascular-Gen.; Antiarteriosclerotic; Hypotensive.    MECHANISM OF ACTION - Sodium-glucose co-transporter 2 inhibitor.    ADMINISTRATION - Administration of (I) is oral. No dosage details given.    EXAMPLE - A suspension of 5 g of amorphous 1-( beta -D-glucopyranosyl)-4-methyl-3-(5-(4-fluorophenyl)-2-thienylmethyl)benzene in 500 ml of water was stirred at room temperature for 18 hours using a magnetic stirrer. The solid material was collected by filtration and dried at 40 degrees C under vacuum (less than 30 mbar) for 24 hours to obtain 4.8 g of 1-( beta -D-glucopyranosyl)-4-methyl-3-(5-(4-fluorophenyl)-2-thienylmethyl)benzene.